Mar 31, 2020
ESSA Pharma Submits IND for EPI-7386 for Prostate Cancer and Provides Business Update
Feb 27, 2020
ESSA Pharma Inc. Reports Results of Annual General and Special Meeting of Shareholders
Feb 13, 2020
ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal First Quarter Ended December 31, 2019
Feb 10, 2020
ESSA Pharma Announces Multiple Abstracts Accepted for Presentation at Upcoming Medical and Scientific Symposia
Dec 19, 2019
ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Fourth Quarter and Year Ended September 30, 2019
Oct 30, 2019
ESSA Pharma Grants Stock Options
Oct 28, 2019
ESSA Pharma Presents Data on EPI-7386 at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
Oct 18, 2019
ESSA Announces Changes to its Board of Directors
Oct 07, 2019
ESSA Pharma Board of Directors Approves Stock Option Plan, RSU Plan and Option Grants
Sep 28, 2019
ESSA Pharma Presents New Data on EPI-7386 at the European Society of Medical Oncology (ESMO) 2019 Congress
Sep 19, 2019
ESSA to Present at Ladenburg Thalmann Healthcare Conference
Sep 05, 2019
ESSA Pharma to Present at H.C. Wainwright 21st Annual Global Investment Conference
Aug 27, 2019
ESSA Pharma Completes Public Offering and Concurrent Private Placement for Aggregate Gross Proceeds of US$36 Million
Aug 23, 2019
ESSA Pharma Announces $36 Million Public Offering of Common Stock and Concurrent Private Placement
Aug 14, 2019
ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Third Quarter Ended June 30, 2019
Jul 31, 2019
ESSA Announces that the Scheme of Arrangement with Realm Therapeutics has become Effective
Jul 30, 2019
ESSA Announces Court Sanction of the Scheme of Arrangement with Realm Therapeutics
Jul 15, 2019
ESSA Expands Leadership Team by appointing Alessandra Cesano as Chief Medical Officer
Jul 08, 2019
ESSA Provides Update on Court Hearing
Jun 26, 2019
ESSA Provides an Update to the Acquisition of Realm Therapeutics